{
    "relation": [
        [
            "",
            "Exenatide BID",
            "Placebo"
        ],
        [
            "Description",
            "Subcutaneous injection of exenatide, twice a day (5 mcg exenatide per dose for first 4 weeks, then 10 mcg exenatide per dose for remainder of 6 months)",
            "Subcutaneous injection of placebo twice a day for 6 months"
        ]
    ],
    "pageTitle": "Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00701935?sect=X0125&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989891.18/warc/CC-MAIN-20150728002309-00007-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 858195370,
    "recordOffset": 858178976,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{2220=Initial planned enrolment was 12 months, starting August 2008. Eventual enrolment time was 3+ years \u2013 decision made to close end of 2011.}",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Initial planned enrolment was 12 months, starting August 2008. Eventual enrolment time was 3+ years \u2013 decision made to close end of 2011. Number of patients initially planned: 94 randomized and 74 completers Final number of patients: 80 randomized and 53 completers Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: placebo Drug: exenatide Interventions: Diabetes Mellitus Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Investigator); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design:",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Exenatide BID \u00a0 \u00a0 Placebo \u00a0 STARTED \u00a0 \u00a0 43 \u00a0 \u00a0 37 \u00a0 COMPLETED \u00a0 \u00a0 27 \u00a0 \u00a0 26 \u00a0 NOT COMPLETED \u00a0 \u00a0 16 \u00a0 \u00a0 11 \u00a0 \u00a0 Baseline Characteristics \u00a0 Hide Baseline Characteristics Population Description Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. No text entered. Reporting",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}